Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.

Clinical molecularly targeted chemoprevention has surged forward since the late 1990s, with several targeted agents that prevent cancers, intraepithelial neoplasias and/or microbial infections ...

Twenty years on, the amended product patent regime has had its moments. And intellectual property experts say it’s time to ...

Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With BRCA Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Specific Membrane Antigen ...

Results: Of the 32, 520, 983 reports in VigiBase, 23, 181, 539 were eligible for the analysis. Significant cardiovascular signals were identified for 17 TKIs, including erlotinib, gefitinib, and ...

随着精准医学发展，肿瘤中的驱动靶点不断被发现，针对这些靶点的靶向治疗也显著改善了患者预后。自 2004 年开始，MET 基因异常开始逐渐走入研究 ...